A new malaria vaccine that’s been tested in Africa could offer a chance of avoiding the deadly disease that has killed more than 6.5 million people and displaced nearly half the continent’s population since it was first discovered in 1976.
The new drug, known as Natalix, was developed by a French company, Takeda, which developed the original malaria vaccine, and is the result of a partnership between the company and a UK-based company called Becton Dickinson, which is also developing the drug.
Takeda says it is the first malaria vaccine to be approved by the Food and Drug Administration in more than 50 years, and the first in the developed world to have a significant number of patients respond to it, although the drug has been approved by several European countries.
Natalix has been shown to help in treating the disease in animals and in humans, but it hasn’t been tested on humans.
What is the problem?
Africans make up just 1.5% of the world’s population, but they are at high risk of contracting malaria, the second leading cause of death in the world after malaria.
In 2015, the disease killed more people than any other infectious disease.
In Africa, the risk of catching the disease increases with the temperature.
The warmer the climate, the greater the risk that a person will contract malaria, according to the World Health Organization.
But unlike in the tropics, in the tropical rainforests of Africa, malaria is endemic.
So far, the only treatment that works against malaria in Africa has been the use of a combination of drugs called “bioequivalents.”
These drugs, known collectively as chemoprophylaxis, have been shown in clinical trials to reduce the risk for developing malaria.
But in many parts of the continent, where malaria is prevalent, this isn’t enough.
Many countries, including many in Africa, have banned chemopropilons, meaning they can’t be given to anyone without a prescription.
But many countries are still in the dark about the effectiveness of this treatment.
Is it safe?
The Cochrane Collaboration, which reviews drugs approved by Cochrane, says Natalux has been proven safe in animal and human trials.
“Our findings demonstrate the safety of Natalox in humans and animals,” said a spokesperson for the Cochrane group.
“Natalox is currently the first treatment approved by regulatory authorities for the treatment of malaria in humans in developed and developing countries.”
The drug is being tested in a trial by the US Food and Drugs Administration.
But there is still more work to do before it can be used in humans.
Until Natalax is approved, Cochrane recommends that people who have a fever or a sore throat and feel a lot of pain avoid touching their feet or touching their face, and use a mask.
However, in addition to the precautionary principle, the company has also proposed that people should stay home if their fever is higher than 60 degrees Fahrenheit (25 degrees Celsius).
It also recommends that those with a fever above 70 degrees Fahrenheit, or who are very tired, wear a mask, if possible.
This is a developing story.
Please check back for updates.